Search

Your search keyword '"Arriola, A."' showing total 112 results

Search Constraints

Start Over You searched for: Author "Arriola, A." Remove constraint Author: "Arriola, A." Journal annals of oncology Remove constraint Journal: annals of oncology
112 results on '"Arriola, A."'

Search Results

1. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

2. 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

3. 1532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results

4. 49P Identifying peripheral immune predictors of durable clinical response to PD-L1 blockade in small cell lung cancer

5. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)

8. 1532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results

10. 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

11. 91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer

13. 142P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab

14. 92P PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis

16. 142P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab

17. 1667TiP Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study

20. 1354P Comparison of different hyperprogressive disease criteria in non-small cell lung cancer patients treated with immunotherapy and correlation with somatic mutations in driver genes

22. 1667TiP Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study

23. 1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study

24. 1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results

25. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain

30. 1476P Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study

31. 1451P Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer

32. 1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

38. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort

41. 1354P Comparison of different hyperprogressive disease criteria in non-small cell lung cancer patients treated with immunotherapy and correlation with somatic mutations in driver genes

44. Desmoplastic round cell tumor: Six cases report and discussion

45. 111P Adenosine pathway and exhaustion markers in peripheral T-cell correlate with benefit from immunotherapy in advanced non-small cell lung cancer

46. Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC

48. Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients

49. Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer

50. Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

Catalog

Books, media, physical & digital resources